Sage/Biogen Zuranolone Study Shows More Efficacy, But Higher Toxicity
Commercial Prospects Still Murky
Executive Summary
Data from SHORELINE’s 50mg cohort sparked mixed opinions from analysts, with some suggesting they still showed a risk-benefit profile that could challenge the drug commercially.